Addex Z Score
ADXN Stock  USD 0.67 0.02 2.90% 
Addex  Z Score 
Addex Z Score Analysis
Addex Therapeutics' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
More About Z Score  All Equity Analysis
2020  2021  2022  2023 (projected)  
Interest Expense  650.63 K  63.01 K  313.26 K  310.16 K 
Gross Profit  3.61 M  2.92 M  1.42 M  2.16 M 
Z Score  =  Sum Of   5 Factors 
Current Addex Therapeutics Z Score  45.88 
Most of Addex Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Addex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Addex Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Addex Therapeutics is extremely important. It helps to project a fair market value of Addex Stock properly, considering its historical fundamentals such as Z Score. Since Addex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Addex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Addex Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a ZScore, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. ZScores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize zscores proved it to be successful as a predictor of corporate bankruptcy.
Competition 
In accordance with the company's disclosures, Addex Therapeutics has a Z Score of 45.88. This is 779.7% lower than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The z score for all United States stocks is notably higher than that of the company.
Addex Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Addex Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Addex Therapeutics could also be used in its relative valuation, which is a method of valuing Addex Therapeutics by comparing valuation metrics of similar companies.Addex Therapeutics is currently under evaluation in z score category among related companies.
Addex Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Addex Therapeutics from analyzing Addex Therapeutics' financial statements. These drivers represent accounts that assess Addex Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Addex Therapeutics' important valuation drivers and their relationship over time.
2018  2019  2020  2021  2022  2023 (projected)  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (1.42 M)  (14.23 M)  (11.83 M)  (14.94 M)  (20.17 M)  (20.7 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (1.45 M)  (14.67 M)  (13.44 M)  (16.42 M)  (21.69 M)  (22.26 M)  
Earnings before Tax  (1.64 M)  (14.78 M)  (12.86 M)  (15.35 M)  (20.8 M)  (21.35 M)  
Free Cash Flow  1.74 M  (9.51 M)  (12.24 M)  (14.74 M)  (16.44 M)  (16.87 M)  
Invested Capital  (1.79 M)  (3.64 M)  (1.57 M)  (1.6 M)  (1.58 M)  (1.71 M)  
Tangible Asset Value  42.21 M  33.03 M  20.18 M  22.54 M  8.28 M  8.5 M  
Working Capital  39.82 M  26.71 M  15.87 M  17.81 M  4.55 M  4.67 M 
Addex Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Addex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Addex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in highprofile magazines, and presentations at investor conferences help move the stock higher, increasing Addex Therapeutics' value.Last Transaction  Type  Shares  Value  
Nea Management Company Llc  20230331  Common Shares  5.6 M  1.1 M  
Armistice Capital Llc  20220930  Common Shares  320 K  256 K  
Endurant Capital Management Lp  20230331  Common Shares  120.7 K  114.3 K  
Old Mission Capital Llc 1  20230331  Common Shares  65.7 K  62.2 K  
Virtu Financial Llc  20230331  Common Shares  42.9 K  41 K  
New Leaf Venture Partners Llc  20220930  Common Shares  50 K  40 K  
Citadel Advisors Llc  20230331  Common Shares  34.4 K  32.5 K  
Fny Investment Advisers Llc  20220930  Common Shares  22.5 K  17 K  
Millennium Management Llc  20220930  Common Shares  20 K  16 K  
Susquehanna International Group Llp  20230331  Common Shares  15.1 K  14.3 K  
Renaissance Technologies Llc  20221231  Common Shares  21.9 K  14 K 
Addex Fundamentals
Return On Equity  (2.04) %  
Return On Asset  (0.86) %  
Operating Margin  (10.07) %  
Current Valuation  3.12 M  
Shares Outstanding  14.81 M  
Shares Owned by Institutions  18.00 %  
Number of Shares Shorted  673.14 K  
Price to Book  1.41 X  
Price to Sales  10.28 X  
Revenue  1.42 M  
Gross Profit  1.44 M  
EBITDA  (20.17 M)  
Net Income  (20.8 M)  
Cash and Equivalents  8.81 M  
Cash per Share  1.40 X  
Total Debt  336.95 K  
Debt to Equity  0.049 %  
Current Ratio  2.55 X  
Book Value Per Share  0.38 X  
Cash Flow from Operations  (16.44 M)  
Short Ratio  0.71 X  
Earnings Per Share  (2.32) X  
Number of Employees  24  
Beta  1.67  
Market Capitalization  11.49 M  
Total Asset  8.28 M  
Retained Earnings  (349.86 M)  
Working Capital  4.55 M  
Current Asset  32.02 M  
Current Liabilities  4.82 M  
Z Score  45.88  
Net Asset  8.28 M 
About Addex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Addex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Addex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Addex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Addex Therapeutics Ltd, a developmentstage biopharmaceutical company, discovers, develops, and commercializes smallmolecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. Addex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Addex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Addex Therapeutics' short interest history, or implied volatility extrapolated from Addex Therapeutics options trading.
Pair Trading with Addex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Addex Stock
Moving against Addex Stock
  0.72  VBLT  Vascular Biogenics  Fiscal Quarter End 30th of June 2023  PairCorr  
  0.64  VCEL  Vericel Corp Ord  Fiscal Quarter End 30th of June 2023  PairCorr  
  0.64  VECT  VectivBio Holding  Report 19th of July 2023  PairCorr  
  0.6  DICE  Dice Molecules Holdings  Fiscal Quarter End 30th of June 2023  PairCorr  
  0.59  DNLI  Denali Therapeutics  Fiscal Quarter End 30th of June 2023  PairCorr 
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Check out Addex Therapeutics Piotroski F Score and Addex Therapeutics Valuation analysis. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Addex Stock analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios  
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated  
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency  
Fundamental Analysis View fundamental data based on most recent published financial statements  
Money Managers Screen money managers from public funds and ETFs managed around the world  
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated  
Money Managers Screen money managers from public funds and ETFs managed around the world  
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios  
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and riskadjusted market performance  
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. 
Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.32)  Revenue Per Share 0.198  Quarterly Revenue Growth 1.058  Return On Assets (0.86)  Return On Equity (2.04) 
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.